Entrectinib can induce sinus bradycardia as a rare but serious cardiac adverse effect in patients with metastatic non-small cell lung cancer.
Does entrectinib cause sinus bradycardia in patients with metastatic non-small cell lung cancer?
Entrectinib, a multikinase inhibitor used for ROS1 fusion-positive NSCLC, is associated with rare but serious cardiac adverse effects such as sinus bradycardia.
Tasa de eventos absoluta: 0% vs 0%
Targeted therapies like tyrosine kinase inhibitors have significantly improved outcomes in non–small cell lung cancer. Entrectinib, a multikinase inhibitor, showed efficacy in ROS1 fusion-positive NSCLC, including intracranial metastases. Although generally well tolerated, rare but serious cardiac adverse effects have been reported.
Talasaz et al. (Sun,) reported a other. Entrectinib can induce sinus bradycardia as a rare but serious cardiac adverse effect in patients with metastatic non-small cell lung cancer.